Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy

Molecular Therapy

Volumn 22, Issue 5, 2014, Pages 929-939

  Sallach, Jessica ^a,b   Di Pasquale, Giovanni ^c   Larcher, Fernando ^d   Niehoff, Nadine ^a,b   Rübsam, Matthias ^a,b   Huber, Anke ^a,b   Chiorini, Jay ^c   Almarza, David ^d,i   Eming, Sabine A ^a,b,e   Ulus, Hikmet ^f   Nishimura, Stephen ^g   Hacker, Ulrich T ^h   Hallek, Michael ^a,b   Niessen, Carien M ^a,b,e   Büning, Hildegard ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d UNIVERSIDAD CARLOS III DE MADRID   (Spain)

^e UNIVERSITY OF COLOGNE   (Germany)

^f Children's Medical Surgery   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h University Cancer Center Leipzig (UCCL)   (Germany)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA8 INTEGRIN; INTEGRIN; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; ALPHA5 INTEGRIN; CAPSID PROTEIN; PEPTIDE;

ANIMAL CELL; ARTICLE; BIOSAFETY; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYO; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; KERATINOCYTE; MOUSE; NONHUMAN; PRIMARY CELL CULTURE; PROTEIN EXPRESSION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SEROTYPE; VIRAL TROPISM; VIRUS CAPSID; VIRUS ENTRY; VIRUS GENOME; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETICS; METABOLISM; PATHOLOGY; SKIN ABNORMALITIES; TROPISM;

MIRIDAE;

CAPSID PROTEINS; DEPENDOVIRUS; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTEGRIN ALPHA5; KERATINOCYTES; PEPTIDES; SKIN ABNORMALITIES; TRANSDUCTION, GENETIC; TROPISM;

EID: 84899970187     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.14     Document Type: Article

References (50)

1. Kubo, A, Nagao, K and Amagai, M (2012. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest 122: 440-447.
2. Simpson, CL, Patel, DM and Green, KJ (2011. Deconstructing the skin: cytoarchitectural determinants of epidermal morphogenesis. Nat Rev Mol Cell Biol 12: 565-580.
3. Fuchs, E (2007. Scratching the surface of skin development. Nature 445: 834-842.
4. Gurtner, GC, Werner, S, Barrandon, Y and Longaker, MT (2008. Wound repair and regeneration. Nature 453: 314-321.
5. Priya, SG, Jungvid, H and Kumar, A (2008. Skin tissue engineering for tissue repair and regeneration. Tissue Eng Part B Rev 14: 105-118.
6. Mingozzi, F and High, KA (2011. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12: 341-355.
7. Büning, H, Perabo, L, Coutelle, O, Quadt-Humme, S and Hallek, M (2008. Recent developments in adeno-associated virus vector technology. J Gene Med 10: 717-733.
8. Braun-Falco, M, Eisenried, A, Büning, H and Ring, J (2005. Recombinant adenoassociated virus type 2-mediated gene transfer into human keratinocytes is influenced by both the ubiquitin/proteasome pathway and epidermal growth factor receptor tyrosine kinase. Arch Dermatol Res 296: 528-535.
9. Ellis, BL, Hirsch, ML, Barker, JC, Connelly, JP, Steininger, RJ 3rd and Porteus, MH (2013. A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9 and one engineered adeno-associated virus serotype. Virol J 10:74.
10. Gagnoux-Palacios, L, Hervouet, C, Spirito, F, Roques, S, Mezzina, M, Danos, O et al. (2005. Assessment of optimal transduction of primary human skin keratinocytes by viral vectors. J Gene Med 7: 1178-1186.
11. Keswani, SG, Balaji, S, Le, L, Leung, A, Lim, FY, Habli, M et al. (2012. Pseudotyped adeno-associated viral vector tropism and transduction efficiencies in murine wound healing. Wound Repair Regen 20: 592-600.
12. Petek, LM, Fleckman, P and Miller, DG (2010. Efficient KRT14 targeting and functional characterization of transplanted human keratinocytes for the treatment of epidermolysis bullosa simplex. Mol Ther 18: 1624-1632.
13. Kronenberg, S, Kleinschmidt, JA and Böttcher, B (2001. Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep 2: 997-1002.
14. Büning, H, Bolyard, CM, Hallek, M and Bartlett, JS (2011. Modification and labeling of AAV vector particles. Methods Mol Biol 807: 273-300.
15. Xie, Q, Bu, W, Bhatia, S, Hare, J, Somasundaram, T, Azzi, A et al. (2002. The atomic structure of adeno-associated virus (AAV-2, a vector for human gene therapy. Proc Natl Acad Sci USA 99: 10405-10410.
16. Kern, A, Schmidt, K, Leder, C, Müller, OJ, Wobus, CE, Bettinger, K et al. (2003. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 77: 11072-11081.
17. Opie, SR, Warrington, KH Jr, Agbandje-McKenna, M, Zolotukhin, S and Muzyczka, N (2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77: 6995-7006.
18. Perabo, L, Goldnau, D, White, K, Endell, J, Boucas, J, Humme, S et al. (2006. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol 80: 7265-7269.
19. Müller, OJ, Kaul, F, Weitzman, MD, Pasqualini, R, Arap, W, Kleinschmidt, JA et al. (2003. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21: 1040-1046.
20. Perabo, L, Büning, H, Kofler, DM, Ried, MU, Girod, A, Wendtner, CM et al. (2003. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 8: 151-157.
21. Varadi, K, Michelfelder, S, Korff, T, Hecker, M, Trepel, M, Katus, HA et al. (2012. Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther 19: 800-809.
22. Asokan, A, Hamra, JB, Govindasamy, L, Agbandje-McKenna, M and Samulski, RJ (2006. Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol 80: 8961-8969.
23. Summerford, C, Bartlett, JS and Samulski, RJ (1999. AlphaVbeta5 integrin: a coreceptor for adeno-associated virus type 2 infection. Nat Med 5: 78-82.
24. Summerford, C and Samulski, RJ (1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438-1445.
25. Asselineau, D, Bernhard, B, Bailly, C and Darmon, M (1985. Epidermal morphogenesis and induction of the 67 kD keratin polypeptide by culture of human keratinocytes at the liquid-air interface. Exp Cell Res 159: 536-539.
26. Di Pasquale, G, Davidson, BL, Stein, CS, Martins, I, Scudiero, D, Monks, A et al. (2003. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9: 1306-1312.
27. Kondratowicz, AS, Lennemann, NJ, Sinn, PL, Davey, RA, Hunt, CL, Moller-Tank, S et al. (2011. T-cell immunoglobulin and mucin domain 1 (TIM-1 is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci USA 108: 8426-8431.
28. Quinn, K, Brindley, MA, Weller, ML, Kaludov, N, Kondratowicz, A, Hunt, CL et al. (2009. Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors. J Virol 83: 10176-10186.
29. Weller, ML, Amornphimoltham, P, Schmidt, M, Wilson, PA, Gutkind, JS and Chiorini, JA (2010. Epidermal growth factor receptor is a co-receptor for adenoassociated virus serotype 6. Nat Med 16: 662-664.
30. Humphries, JD, Byron, A and Humphries, MJ (2006. Integrin ligands at a glance. J Cell Sci 119(Pt 19: 3901-3903.
31. Jackson, T, Clark, S, Berryman, S, Burman, A, Cambier, S, Mu, D et al. (2004. Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: role of the betachain cytodomain in integrin-mediated infection. J Virol 78: 4533-4540.
32. Mu, D, Cambier, S, Fjellbirkeland, L, Baron, JL, Munger, JS, Kawakatsu, H et al. (2002. The integrin alpha(vbeta8 mediates epithelial homeostasis through MT1-MMPdependent activation of TGF-beta1. J Cell Biol 157: 493-507.
33. Johns, HL, Berryman, S, Monaghan, P, Belsham, GJ and Jackson, T (2009. A dominant-negative mutant of rab5 inhibits infection of cells by foot-and-mouth disease virus: implications for virus entry. J Virol 83: 6247-6256.
34. Wang, LH, Rothberg, KG and Anderson, RG (1993. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 123: 1107-1117.
35. Van Hamme, E, Dewerchin, HL, Cornelissen, E, Verhasselt, B and Nauwynck, HJ (2008. Clathrin-and caveolae-independent entry of feline infectious peritonitis virus in monocytes depends on dynamin. J Gen Virol 89(Pt 9: 2147-2156.
36. Eming, SA, Krieg, T and Davidson, JM (2007. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 127: 514-525.
37. Schechner, JS, Crane, SK, Wang, F, Szeglin, AM, Tellides, G, Lorber, MI et al. (2003. Engraftment of a vascularized human skin equivalent. FASEB J 17: 2250-2256.
38. De Luca, M, Pellegrini, G and Mavilio, F (2009. Gene therapy of inherited skin adhesion disorders: a critical overview. Br J Dermatol 161: 19-24.
39. Zhong, L, Li, B, Jayandharan, G, Mah, CS, Govindasamy, L, Agbandje-McKenna, M et al. (2008. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381: 194-202.
40. Zhong, L, Li, B, Mah, CS, Govindasamy, L, Agbandje-McKenna, M, Cooper, M et al. (2008. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 105: 7827-7832.
41. Grimm, D, Lee, JS, Wang, L, Desai, T, Akache, B, Storm, TA et al. (2008. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 82: 5887-5911.
42. Michelfelder, S, Kohlschütter, J, Skorupa, A, Pfennings, S, Müller, O, Kleinschmidt, JA et al. (2009. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS ONE 4: e5122.
43. Naumer, M, Ying, Y, Michelfelder, S, Reuter, A, Trepel, M, Müller, OJ et al. (2012. Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions. Hum Gene Ther 23: 492-507.
44. Ying, Y, Müller, OJ, Goehringer, C, Leuchs, B, Trepel, M, Katus, HA et al. (2010. Hearttargeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther 17: 980-990.
45. Uhrig, S, Coutelle, O, Wiehe, T, Perabo, L, Hallek, M and Büning, H (2012. Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther 19: 210-218.
46. Cambier, S, Mu, DZ, O'Connell, D, Boylen, K, Travis, W, Liu, WH et al. (2000. A role for the integrin alphavbeta8 in the negative regulation of epithelial cell growth. Cancer Res 60: 7084-7093.
47. Stachelscheid, H, Ibrahim, H, Koch, L, Schmitz, A, Tscharntke, M, Wunderlich, FT et al. (2008. Epidermal insulin/IGF-1 signalling control interfollicular morphogenesis and proliferative potential through Rac activation. EMBO J 27: 2091-2101.
48. Girod, A, Ried, M, Wobus, C, Lahm, H, Leike, K, Kleinschmidt, J et al. (1999. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 5: 1052-1056.
49. Hacker, UT, Wingenfeld, L, Kofler, DM, Schuhmann, NK, Lutz, S, Herold, T et al. (2005. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J Gene Med 7: 1429-1438.
50. Xiao, X, Li, J and Samulski, RJ (1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232.